

Norway



Recent and planned developments in pharmaceutical policies 2017/2018

Special topic: patient involvement in pricing and reimbursement of medicines

CHANGES IN PRICING

- 01/01/2018:** More regressive pharmacy mark-up
- Pharmacy Purchasing Price 200<NOK (22 EUR); percentage mark-up reduced from 7% to 2,25%, mark-up per pack increased from 25 to 29 NOK
 - Introduction of 0,5% mark-up for cooled products
 - Introduction of minimum prices for stepped price (50NOK)

01/01/2018:

- Increase of control fee (to be paid by pharmaceutical company) from 0.7% to 1% of PPP
- Significant reduction (50%) of fee for marketing licences in return

01/05/2018: Seretide and Symbicort are substitutable and will be subject to stepped price cuts

CHANGES IN REIMBURSEMENT

2018 More medicines were moved from National Insurance Scheme to Regional Health Authority's budget:

- HIV, Hepatitt B/C, Severe Asthma

01/01/2018 All publicly financed drugs need to undergo an HTA

- NoMA is responsible for assessment
- Intended to lead to more cost-effective use of drugs – NoMA and Drug Procurement Cooperation are assessing options for faster
- Severity of disease (next to resource requirements and effectiveness) is criteria for HTA

- Inhalation guidance in pharmacies extended by 3 years
- HTA process collaboration launched with Sweden and Finland (on-going)

SPECIAL TOPIC: Patient Involvement in Pricing and Reimbursement of Medicines

HTA procedures

- Patient association involvement as pilots (e.g. Spinraza)
- Clinicians involvement in HTA process

Hospital tenders

- Regular involvement of patient associations in expert groups (tender processes)